Medicinal therapy of benign prostate syndrome.
Summary of "Medicinal therapy of benign prostate syndrome."
Male lower urinary tract symptoms (LUTS) include storage and voiding disorders and should be carefully evaluated before the start of any treatment. Medical therapy is directed at improving symptoms and reducing the risk of progression in order to improve quality of life and prevent complications, such as acute urinary retention, or the need for surgical intervention. Careful assessment of the individual complaints helps to identify the best drug which should be adapted to each individual patient's risk profile. At present, α(1)-adrenoreceptor inhibitors and 5-alpha reductase inhibitors and their combination form the gold standard for pharmacological treatment. In addition, anticholinergic agents are increasingly being used as monotherapy or in combination with α1-adrenocepetor inhibitors for patients with predominant storage disorders while phosphodiesterase 5 (PDE5) inhibitors may be suitable for patients suffering from LUTS and concomitant erectile dysfunction.
Affiliation
Urologische Klinik und Poliklinik, Klinikum der Universität München-Großhadern , Marchioninistr. 15, 81377, München, Deutschland, Frank.Strittmatter@med.uni-muenchen.de.
Journal Details
This article was published in the following journal.
Name: Der Urologe. Ausg. A
ISSN: 1433-0563
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22782192
- DOI: http://dx.doi.org/10.1007/s00120-012-2943-1
Medical and Biotech [MESH] Definitions
Ultrasound, High-intensity Focused, Transrectal
Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).
Prostatic Secretory Proteins
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
Prostate-specific Antigen
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Transurethral Resection Of Prostate
Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.
Neoadjuvant Therapy
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
PubMed Articles
Testosterone Replacement Therapy and Prostate Health.
There is an emerging evolution in the understanding of the relationship between the prostate and testosterone. It has long been generally believed that with testosterone replacement therapy (TRT), inc...
Documentation of the Governing Body of Prostate Centers (DVPZ).
For certification of a prostate center according to the guidelines of the Governing Body of Prostate Centers (DVPZ) an amalgamation of at least five practicing urologists with a main urology departmen...
Medicinal treatment is the primary conservative treatment option for patients with moderate to severe lower urinary tract symptoms (LUTS). Monotherapy with alpha-blockers may be a suitable option for...
Nonneoplastic lesions of the prostate and bladder.
Context.-Specimens from the prostate and bladder are commonly encountered by the general surgical pathologist. Emphasis is usually placed on neoplasms of the bladder and prostate, particularly if mali...
Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia.
PURPOSE: Benign prostatic hyperplasia is a common urinary tract disorder that affects aging men. The molecular mechanisms underlying benign prostatic hyperplasia are obscure and the development of ani...
Clinical Trials
Efficacy and Safety of Nocturin® 0,1 mg Tablets in Nocturia in Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of Nocturin® 0,1 mg Tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated...
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and po...
Imaging of Prostate Cancer Using Two-Dimensional MR Spectroscopy and Diffusion Tensor Imaging
The goal is to develop MR imaging techniques to improve delineation of cancer extent, and to improve differential diagnosis between prostate cancer and benign prostate hyperplasia or other...
Kinetics of the Finasteride Prostate Induced Apoptosis
The aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (BPH). Five sets of patients who need a s...
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT,...
